



### **Co-ordination of PRINCIPLE and STOP-COVID19 Trials**

PRINCIPLE is a platform, response adaptive, open-label multi-centre randomised study of patients in primary care. It is studying the impact of drugs on the need for admission to hospital or death.

STOP-COVID19 is a UK randomized trial being conducted in 15 UK centres to test whether Brensocatib compared with placebo improves clinical outcomes and reduces mortality in COVID-19 patients admitted to hospital.

### **PRINCIPLE and STOP-COVID have agreed that:**

- Patients admitted to a participating hospital may be enrolled into the STOP-COVID19 trial
- The previous receipt of azithromycin or doxycycline, the current intervention arms in PRINCIPLE, are not a contraindication to co-enrolment into the STOP-COVID19 trial
- Participants in the community-based PRINCIPLE trial will be given a card to indicate that they are participating in the trial. If admitted to hospital, they will endeavour to inform the care team of their participation in PRINCIPLE. They may also have a trial partner (someone who is helping them with trial procedures) who will also be able to inform hospital teams about a patient's study involvement.
- PRINCIPLE and STOP-COVID19 will work closely together to share information on participating sites, interventions, and co-enrolments.

10<sup>th</sup> September 2020